Research Analysts Set Expectations for ENSC FY2027 Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Analysts at Zacks Research issued their FY2027 earnings estimates for shares of Ensysce Biosciences in a report issued on Tuesday, March 31st. Zacks Research analyst B. Sorensen expects that the company will earn ($0.20) per share for the year. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Ensysce Biosciences Price Performance

NASDAQ ENSC opened at $0.61 on Wednesday. Ensysce Biosciences has a 1 year low of $0.31 and a 1 year high of $4.85. The company has a market capitalization of $2.21 million, a PE ratio of -0.14 and a beta of 1.12. The company has a fifty day moving average of $0.54 and a two-hundred day moving average of $1.32.

Ensysce Biosciences (NASDAQ:ENSC) last posted its earnings results on Monday, March 30th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.51. Ensysce Biosciences had a negative net margin of 200.87% and a negative return on equity of 458.65%. The firm had revenue of $1.88 million for the quarter, compared to the consensus estimate of $0.50 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. TRU Independence Asset Management 2 LLC purchased a new stake in shares of Ensysce Biosciences in the third quarter valued at about $25,000. Citadel Advisors LLC acquired a new position in Ensysce Biosciences in the 3rd quarter valued at about $34,000. Virtu Financial LLC acquired a new position in Ensysce Biosciences in the 3rd quarter valued at about $34,000. DRW Securities LLC raised its stake in Ensysce Biosciences by 42.4% during the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after acquiring an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in Ensysce Biosciences by 100.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after acquiring an additional 75,000 shares during the last quarter. 5.63% of the stock is owned by hedge funds and other institutional investors.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.